EAU 2019

The European Association of Urology (EAU) held its annual congress in Barcelona, Spain this month. There were presentations about partial nephrectomy, neoadjuvant treatment of renal cell carcinoma (RCC), and the management of RCC. Here are some of the more interesting RCC presentations for you to browse through: EAU 2019: The Challenging Landscape in Advanced Renal […]

read more

Hand-foot syndrome as a predictor of better outcomes in patients treated with sunitinib

A recent study, published in the journal Advances in Medicine and Medical Research, suggests that the presence of hand-foot syndrome in patients with metastatic renal cell carcinoma (RCC) after the first cycle of treatment with sunitinib predicts longer progression-free survival. Median progression-free survival was 9.8 months in those patients who did not experience hand-foot syndrome […]

read more

Phytochemicals and cancer

Phytochemicals are compounds produced by plants to give them their colour, smell or taste. They have a number of different functions, such as deterring predators or responding to tissue damage or infection. Some phytochemicals are believed to have human health benefits as a result of their antioxidant, anti-inflammatory, or antiproliferative activity, and are also thought […]

read more

Cryoablation versus partial nephrectomy for early stage renal masses

A recent study, published in the Journal of Cancer, conducted a systematic review and meta-analysis of the outcomes data for the use of cryoablation versus partial nephrectomy for early stage (T1) renal tumours. The review showed that cryoablation is linked with poorer oncologic outcomes than partial nephrectomy, but patients who underwent cryoablation had lower rates […]

read more

Syntaxin 6: A potential biomarker for papillary renal cell carcinoma

A recent study published in Scientific Reports last month has identified Syntaxin 6, a protein known to play an important role in the movement of protein and lipids within cells (intracellular trafficking), as a prognostic biomarker for patients with a type of kidney cancer called papillary renal cell carcinoma (RCC). Syntaxin 6 also holds promise […]

read more

Tivozanib included in new European guidelines for kidney cancer

Tivozanib has been included as a first-line treatment recommendation for advanced renal cell carcinoma (aRCC) in new European Society of Medical Oncology (ESMO) clinical practice guidelines for RCC, published last month. Tivozanib is recommended as a first-line treatment option for people with advanced clear cell RCC of good (favourable) risk or intermediate risk. Tivozanib is a potent selective vascular endothelial growth factor […]

read more

Potential prognostic biomarker for kidney cancer

A recent study, published in the European Review for Medical and Pharmacological Sciences last month, identified tyrosine kinase receptor (TEK) as a potential novel prognostic biomarker for clear cell renal cell carcinoma (ccRCC). TEK is a protein receptor found on the surface of tumour cells. It plays an important role in the growth of new […]

read more

Microwave ablation for early stage renal masses

Researchers from the Mayo Clinic in Rochester, USA, have published a retrospective review of the use of microwave ablation in the American Journal of Roentgenology (AJR). The review describes percutaneous (through the skin) microwave ablation as a promising treatment for patients with early stage (T1) renal tumours. However, more research into the selection of patients due to […]

read more

Higher vitamin D levels associated with lower likelihood of kidney cancer

A new study, published in the International Brazilian Journal of Urology, shows that higher circulating concentrations of 25-hydroxyvitamin D in the blood are associated with a lower risk of renal cell carcinoma (RCC). The study, conducted in China, compared 135 newly diagnosed cases of RCC with 135 controls matched by age and sex. The investigators […]

read more

Cabozantinib in advanced non-clear cell kidney cancer

A recent study, published in The Lancet Oncology, has provided evidence of the effectiveness of cabozantinib for patients with non-clear cell renal cell carcinoma (RCC). This real world study identified 112 patients with non-clear cell RCC treated with cabozantinib at hospitals in the USA and Belgium. Most had papillary histology (66 patients, 59%), 17 (15%) […]

read more
Showing 1 to 10 of 479 results
  TOP